

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# Innovent

信達生物製藥

**INNOVENT BIOLOGICS, INC.**

*(Incorporated in the Cayman Islands with Limited Liability)*

**(Stock Code: 1801)**

## TERMINATION OF CONNECTED TRANSACTION

Reference is made to the announcement of the Company dated October 25, 2024 in relation to the Proposed Subscription (the “**Announcement**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board announces that Fortvita and Lostrancos have, after further consideration, mutually agreed to terminate the Subscription Agreement by a termination agreement entered into between Fortvita and Lostrancos on November 3, 2024. Accordingly, both parties will be released and discharged from their respective rights and obligations under the Subscription Agreement.

The Company reaffirms its positive outlook on growing its international business and Fortvita’s role in driving these efforts toward the long-term goal of becoming a global biopharmaceutical company. In the meanwhile, the focus of the management team has always been on creating long-term value for Innovent and its shareholders. The Proposed Subscription was made with the intention of demonstrating management’s commitment to the Company’s international business in the long run. However, since announcing the Proposed Subscription on October 25, 2024, the Company has received feedback from shareholders on different views on the Proposed Subscription. The Company and the Board have carefully considered the matter and have decided not to proceed with the Proposed Subscription. Consequently Fortvita and Lostrancos have mutually agreed to terminate the Subscription Agreement.

The Company remains fully committed to its strategic objectives and will continue investing in the long-term growth of its international business. As compared with proceeding with the Proposed Subscription at the current time and in its current format, termination of the Proposed Subscription is fair and reasonable, and can better serve the interests of the Company and its shareholders as a whole.

By Order of the Board  
**Innovent Biologics, Inc.**  
**Dr. De-Chao Michael Yu**  
*Chairman and Executive Director*

Hong Kong, November 3, 2024

*As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as Executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-yin Hsu, Dr. Kaixian Chen, Mr. Gary Zieziula, Dr. Shun Lu and Mr. Shuyun Chen as Independent Non-executive Directors.*